BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17169786)

  • 1. What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma?
    Crump M
    Leuk Lymphoma; 2006 Dec; 47(12):2437-9. PubMed ID: 17169786
    [No Abstract]   [Full Text] [Related]  

  • 2. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis.
    Mey UJ; Olivieri A; Orlopp KS; Rabe C; Strehl JW; Gorschlueter M; Hensel M; Flieger D; Glasmacher AG; Schmidt-Wolf IG
    Leuk Lymphoma; 2006 Dec; 47(12):2558-66. PubMed ID: 17169800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
    Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome.
    Martín A; Caballero MD;
    Haematologica; 2009 May; 94(5):744. PubMed ID: 19336744
    [No Abstract]   [Full Text] [Related]  

  • 5. A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-Cell and T-Cell non-Hodgkin's lymphoma.
    Crump M; Shepherd L; Lin B
    Clin Lymphoma; 2005 Jun; 6(1):56-60. PubMed ID: 15989710
    [No Abstract]   [Full Text] [Related]  

  • 6. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
    Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
    Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
    Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma.
    Ueda K; Nannya Y; Asai T; Yamamoto G; Hangaishi A; Takahashi T; Imai T; Kurokawa M
    J Chemother; 2010 Feb; 22(1):54-7. PubMed ID: 20227994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.
    Kang HJ; Kim WS; Suh C; Park YH; Kim BS; Yuh YJ; Ryoo BY
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):299-304. PubMed ID: 17922274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
    Kirschey S; Flohr T; Wolf HH; Frickhofen N; Gramatzki M; Link H; Basara N; Peter N; Meyer RG; Schmitz N; Weidmann E; Banat A; Schulz A; Kolbe K; Derigs G; Theobald M; Hess G
    Br J Haematol; 2015 Mar; 168(6):824-34. PubMed ID: 25546611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
    Gisselbrecht C
    Hematology Am Soc Hematol Educ Program; 2012; 2012():410-6. PubMed ID: 23233612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R-DHAP: a good small step, but not the journey's end.
    McLaughlin P; Vose JM
    Leuk Lymphoma; 2008 Jun; 49(6):1019-21. PubMed ID: 18452108
    [No Abstract]   [Full Text] [Related]  

  • 14. [B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody].
    Ishihara T; Kanagawa M; Koyama J; Hasegawa K; Suzuki T; Hirayama Y; Terui T
    Rinsho Ketsueki; 2014 Nov; 55(11):2283-7. PubMed ID: 25501408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma.
    Woehrer S; Hejna M; Skrabs C; Drach J; Zielinski CC; Jaeger U; Raderer M
    Oncology; 2005; 69(6):499-502. PubMed ID: 16424679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma.
    Palmowski M; Zechmann C; Satzl S; Bartling S; Hallscheidt P
    Ann Hematol; 2008 Apr; 87(4):337-8. PubMed ID: 17929016
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
    Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
    [No Abstract]   [Full Text] [Related]  

  • 18. Ofatumumab in diffuse large B cell lymphoma?
    Gisselbrecht C
    Blood; 2013 Jul; 122(4):469-70. PubMed ID: 23886773
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab refractory patients.
    Sieniawski M; Bhartia S; Wilkinson J; Proctor SJ
    Leuk Lymphoma; 2009 Oct; 50(10):1726-30. PubMed ID: 19639513
    [No Abstract]   [Full Text] [Related]  

  • 20. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
    van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
    J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.